TNF Blockers Linked to Lymphoma

JUNE 01, 2005

Certain arthritis medications known as "TNF [tumor necrosis factor] blockers" may treat rheumatoid arthritis, but they also may increase the risk for lymphoma, according to the results of a recent study from Lund University Hospital in Sweden. TNF is a naturally occurring protein made by the immune system. Certain types of arthritis-such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis-are associated with having too much TNF, which can contribute to pain, swelling, and stiffness.

Researchers analyzed data from 757 Swedish patients being treating with TNF blockers and compared the data with those of 800 patients being treated with conventional antirheumatic drugs. Follow-up data revealed that the TNF-blocker group had 16 tumors, 5 of which were lymphomas. In the conventional group, 69 tumors were identified, including 2 lymphomas. Data analysis showed that the patients treated with TNF blockers were almost 5 times as likely to develop lymphoma. Researchers note that the TNF blocker group had no increased risk for cancer overall.



SHARE THIS SHARE THIS
0
 

The Oncology Care Pharmacist in Health-System Pharmacy 
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.


 

 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.